Semaglutide

Overview

Semaglutide is a once-weekly injectable GLP-1 receptor agonist that has revolutionized both diabetes and weight management treatment. Originally developed for type 2 diabetes as Ozempic, it gained widespread attention when clinical trials demonstrated strong weight loss efficacy, leading to FDA approval as Wegovy for chronic weight management.

As a GLP-1 receptor agonist, semaglutide mimics the natural hormone GLP-1, which regulates blood sugar and appetite. Clinical trials have shown average weight loss of 15-17% of body weight, making it one of the most effective non-surgical weight loss medications available. An oral formulation (Rybelsus) is also available for diabetes treatment.

Semaglutide has fundamentally changed the landscape of obesity medicine and metabolic health, offering hope to millions struggling with weight management and providing significant cardiovascular benefits beyond weight loss.

How It Works

Semaglutide activates GLP-1 receptors throughout the body, creating multiple beneficial effects:

• Gastric emptying delay: Slows food movement from stomach to intestines, promoting satiety
• Appetite suppression: Acts on hypothalamic centers to reduce hunger and food cravings
• Glucose regulation: Enhances insulin secretion only when glucose levels are elevated
• Glucagon suppression: Reduces inappropriate glucose release from the liver
• Beta-cell preservation: Protects and potentially regenerates insulin-producing cells
• Neural pathways: Directly affects brain centers controlling appetite and reward

Benefits

• Significant weight loss: 15-17% average body weight reduction in trials
• Sustained results: Weight loss maintained with continued treatment
• Cardiovascular protection: 20% reduction in major cardiovascular events (SELECT trial)
• Blood sugar control: Excellent A1C reductions in diabetic patients
• Blood pressure reduction: Clinically meaningful BP improvements
• Lipid improvements: Better cholesterol and triglyceride profiles
• Reduced food preoccupation: Decreased "food noise" and cravings
• Quality of life: Improved physical functioning and energy levels

Potential Risks & Side Effects

Common Gastrointestinal Effects

• Nausea (most common, typically improves over time)
• Vomiting and diarrhea
• Constipation
• Abdominal pain
• Decreased appetite
• Acid reflux (GERD)
• Bloating and gas

Serious Potential Risks

• Pancreatitis: Rare but serious pancreatic inflammation
• Gallbladder disease: Increased risk of gallstones and cholecystitis
• Thyroid C-cell tumors: Theoretical risk based on rodent studies
• Severe hypoglycemia: When used with insulin or sulfonylureas
• Kidney problems: Acute kidney injury risk from dehydration
• Diabetic retinopathy: Rapid glucose improvements may worsen retinopathy
• Gastroparesis: Severe delayed gastric emptying (rare)

Typical Protocol

Wegovy (Weight Management) Dosing

• Month 1 (Weeks 1-4): 0.25 mg once weekly
• Month 2 (Weeks 5-8): 0.5 mg once weekly
• Month 3 (Weeks 9-12): 1.0 mg once weekly
• Month 4 (Weeks 13-16): 1.7 mg once weekly
• Maintenance: 2.4 mg once weekly

Ozempic (Diabetes) Dosing

• Starting dose: 0.25 mg once weekly for 4 weeks
• Increase to: 0.5 mg once weekly
• May increase to: 1.0 mg once weekly after 4+ weeks
• Maximum: 2.0 mg once weekly if additional control needed

Administration Guidelines

• Subcutaneous injection in thigh, abdomen, or upper arm
• Rotate injection sites weekly
• Same day each week, any time of day
• Can be taken with or without food
• If dose missed, take within 5 days or skip to next dose

Monitoring Requirements

• Regular weight and BMI tracking
• Blood glucose monitoring (especially if diabetic)
• Kidney function tests
• Monitor for signs of pancreatitis or gallbladder issues
• Thyroid function if family history of thyroid cancer

Reconstitution Guide

Note: Brand name semaglutide (Ozempic/Wegovy) comes in pre-filled pens requiring no reconstitution. For compounded semaglutide:

• Solvent: Bacteriostatic water for injection (preferred) or sterile water
• pH: Target pH 7.0-8.5 for optimal stability
• Mixing technique: Add solvent slowly down vial wall, gently swirl (avoid vigorous shaking)
• Storage: Reconstituted solution stable 28-35 days refrigerated (2-8°C)
• Concentration: Common concentrations 1-5 mg/mL for accurate dosing
• Appearance: Should be clear and colorless, free of particles
• Sterility: Use proper aseptic technique throughout process

Research Citations

Related Compounds